Autoimmune Bullous Disorders induced by Cyclin-Dependent Kinase 4/6 inhibitors – first case series from the EADV Task Force “Dermatology for Cancer Patients”

Autoimmune Bullous Disorders induced by Cyclin-Dependent Kinase 4/6 inhibitors – first case series from the EADV Task Force “Dermatology for Cancer Patients”

Saved in:

Bibliographic Details
Main Authors:	A. Ortiz Brugués, P. Sollena, M. Starace, F. Bardazzi, D. Koumaki, Z. Apalla, M. Iorizzo, C. Bost, S. Milesi, J.L. Lacaze, K. Peris, V. Sibaud
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Series:	EJC Skin Cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772611824001848
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

RESCUE STUDY – International Survey on training of Dermatology Residents in Supportive Oncodermatology
by: A. Ortiz Brugués, et al.
Published: (2024-01-01)

Bullous pemphigoid as a diagnostic and therapeutic challenge with a wide spectrum of dermatological symptoms
by: Przemysław Borowy, et al.
Published: (2025-01-01)

Curcumin: Synthesis optimization and in silico interaction with cyclin dependent kinase
by: Ahmed Mahmood, et al.
Published: (2017-09-01)

Cyclin-Dependent Kinase Inhibitors in the Rare Subtypes of Melanoma Therapy
by: Jonatan Kaszubski, et al.
Published: (2024-11-01)

Cyclin-dependent protein kinases and cell cycle regulation in biology and disease
by: Ilenia Pellarin, et al.
Published: (2025-01-01)

Identification of novel cyclin-dependent kinase 4/6 inhibitors from marine natural products
by: Abhijit Debnath, et al.
Published: (2025-01-01)

Targeting the cyclin-dependent kinase family in anticancer drug discovery: From computational to experimental studies
by: Priyanka Solanki, et al.
Published: (2024-12-01)

Influence of ethnicity on cyclin-dependent kinase inhibitor efficacy and toxicity: A systematic review and meta-analysis
by: Roberto Buonaiuto, et al.
Published: (2025-02-01)

Regulation of the G1/S Transition in Hepatocytes: Involvement of the Cyclin-Dependent Kinase Cdk1 in the DNA Replication
by: Anne Corlu, et al.
Published: (2012-01-01)

Evaluation of anticancer therapy- related dermatologic adverse events: insights from fda's faers dataset
by: S. Salah, et al.
Published: (2024-01-01)

The Prognostic Value and Overexpression of Cyclin A Is Correlated with Gene Amplification of both Cyclin A and Cyclin E in Breast Cancer Patient
by: A. Husdal, et al.
Published: (2006-01-01)

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them
by: L. Foffano, et al.
Published: (2025-02-01)

Cyclin-Dependent Kinase 5/p35/p39: A Novel and Imminent Therapeutic Target for Diabetes Mellitus
by: Danish Ahmed, et al.
Published: (2011-01-01)

Alsterpaullone, a Cyclin-Dependent Kinase Inhibitor, Mediated Toxicity in HeLa Cells through Apoptosis-Inducing Effect
by: Chunying Cui, et al.
Published: (2013-01-01)

Prevalence and Risk of Immunostimulatory Herbal Supplement Treatment Among Autoimmune Dermatology Patients
by: Daniella F. Faden, et al.
Published: (2024-12-01)

Bullous Scabies in an Immunocompromised Host
by: James R. Wester, et al.
Published: (2022-01-01)

Timing of Dose Reductions and Survival Outcomes in Metastatic Breast Cancer Patients Treated with Cyclin-Dependent Kinase 4/6 Inhibitors
by: Pınar Kubilay Tolunay, et al.
Published: (2024-11-01)

Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers
by: Daehwan Kim, et al.
Published: (2025-01-01)

Cyclin-Dependent Kinase-Like 5 (CDKL5): Possible Cellular Signalling Targets and Involvement in CDKL5 Deficiency Disorder
by: Syouichi Katayama, et al.
Published: (2020-01-01)

Linear IgA bullous dermatosis–a fifty year experience of Warsaw Center of bullous diseases
by: Cezary Kowalewski, et al.
Published: (2025-01-01)

Bullous mastocytosis: a Case Report
by: Galal El Enany, et al.
Published: (2024-05-01)

Cocaine-Induced Giant Bullous Emphysema
by: Steven Douedi, et al.
Published: (2020-01-01)

Treatment of Bullous Systemic Lupus Erythematosus
by: Lihua Duan, et al.
Published: (2015-01-01)

Association between cyclin-dependent kinase 4/6 inhibitors and nephrotoxicity in patients with breast cancer: A Systematic Review and meta-analysis
by: Jiayong Cui, et al.
Published: (2024-12-01)

Exploring Pediatric Dermatology in Skin of Color: Focus on Dermoscopy
by: Emmanouil Karampinis, et al.
Published: (2024-12-01)

Cyclin-dependent kinases (CDKs) are key genes regulating early development of Neptunea arthritica cumingii: evidence from comparative transcriptome and proteome analyses
by: Fengxiao Lv, et al.
Published: (2024-12-01)

Meta-analysis: p16INK4α (Cyclin Dependent Kinase Inhibitor 2A) is one of the major causes of nasopharyngeal cancer
by: Lao Đức Thuận, et al.
Published: (2024-04-01)

The Effects of Anlotinib Combined with Chemotherapy following Progression on Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor-Positive Metastatic Breast Cancer
by: Ting Xu, et al.
Published: (2024-01-01)

Design, Molecular Docking, Synthesis, Characterization and Preliminary Evaluation of Novel 1,3,4-Oxadiazole Derivatives as Cyclin-Dependent Kinase 2 Inhibitors
by: Yousef Sabah Ali, et al.
Published: (2025-01-01)

Evaluating the Effectiveness of Cyclin-Dependent Kinase 4/6 Inhibitors in Early- and Very Early-Onset Metastatic Breast Cancer: A Multicenter Study
by: Akif Doğan, et al.
Published: (2025-01-01)

Palbociclib-induced Toxic Epidermal Necrolysis: A Case Report with Review of All Cases Secondary to Cyclin-dependent Kinase 4/6 Inhibitors
by: Aurore Devoldere, et al.
Published: (2025-01-01)

The role of FDG PET assessment in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 inhibitors in the second-line setting
by: Marcin Kubeczko, et al.
Published: (2024-12-01)

Bullous pemphigoid and morphea: Coexistence or an incidental association
by: Seema Rani, et al.
Published: (2024-12-01)

Expression of Selected Integrins and Selectins in Bullous Pemphigoid
by: El&#x17C;bieta Waszczykowska, et al.
Published: (2007-01-01)

Esophageal Involvement and Bleeding in Bullous Pemphigoid Disease
by: Kerem Kenarlı, et al.
Published: (2024-11-01)

Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2– breast cancer (LEADER)
by: Laura M. Spring, et al.
Published: (2025-01-01)

Deletion of cyclin dependent kinase inhibitor 2a gene as a marker of oropharyngeal carcinomas non-associated with human papillomavirus and its prognostic value
by: I.S. Shponka, et al.
Published: (2024-06-01)

Janus kinase inhibitors and adverse events of acne in dermatologic indications: a systematic review and network meta-analysis
by: Bai-lin Chen, et al.
Published: (2024-12-01)

Dermatology /
by: Falco, Braun O. et..al
Published: (1991)

IL-17 Expression in Dermatitis Herpetiformis and Bullous Pemphigoid
by: Agnieszka Zebrowska, et al.
Published: (2013-01-01)